Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Multiple renal cancer susceptibility polymorphisms modulate the HIF pathway.

Grampp S, Schmid V, Salama R, Lauer V, Kranz F, Platt JL, Smythies J, Choudhry H, Goppelt-Struebe M, Ratcliffe PJ, Mole DR, Schödel J.

PLoS Genet. 2017 Jul 17;13(7):e1006872. doi: 10.1371/journal.pgen.1006872. eCollection 2017 Jul.

2.

Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer.

Grampp S, Platt JL, Lauer V, Salama R, Kranz F, Neumann VK, Wach S, Stöhr C, Hartmann A, Eckardt KU, Ratcliffe PJ, Mole DR, Schödel J.

Nat Commun. 2016 Oct 24;7:13183. doi: 10.1038/ncomms13183.

3.

Clinical features of the pathogenic m.5540G>A mitochondrial transfer RNA tryptophan gene mutation.

Ng YS, Hardy SA, Shrier V, Quaghebeur G, Mole DR, Daniels MJ, Downes SM, Freebody J, Fratter C, Hofer M, Nemeth AH, Poulton J, Taylor RW.

Neuromuscul Disord. 2016 Oct;26(10):702-705. doi: 10.1016/j.nmd.2016.08.009. Epub 2016 Aug 17.

4.

Capture-C reveals preformed chromatin interactions between HIF-binding sites and distant promoters.

Platt JL, Salama R, Smythies J, Choudhry H, Davies JO, Hughes JR, Ratcliffe PJ, Mole DR.

EMBO Rep. 2016 Oct;17(10):1410-1421. Epub 2016 Aug 8.

5.

Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases.

Chan MC, Ilott NE, Schödel J, Sims D, Tumber A, Lippl K, Mole DR, Pugh CW, Ratcliffe PJ, Ponting CP, Schofield CJ.

J Biol Chem. 2016 Sep 23;291(39):20661-73. doi: 10.1074/jbc.M116.749291. Epub 2016 Aug 8.

6.

Suppression of plasma hepcidin by venesection during steady-state hypoxia.

Talbot NP, Smith TG, Lakhal-Littleton S, Gülsever C, Rivera-Ch M, Dorrington KL, Mole DR, Robbins PA.

Blood. 2016 Mar 3;127(9):1206-7. doi: 10.1182/blood-2015-05-647404. Epub 2016 Jan 15. No abstract available.

7.

Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.

Messai Y, Gad S, Noman MZ, Le Teuff G, Couve S, Janji B, Kammerer SF, Rioux-Leclerc N, Hasmim M, Ferlicot S, Baud V, Mejean A, Mole DR, Richard S, Eggermont AM, Albiges L, Mami-Chouaib F, Escudier B, Chouaib S.

Eur Urol. 2016 Oct;70(4):623-632. doi: 10.1016/j.eururo.2015.11.029. Epub 2015 Dec 23.

PMID:
26707870
8.

Hypoxic regulation of the noncoding genome and NEAT1.

Choudhry H, Mole DR.

Brief Funct Genomics. 2016 May;15(3):174-85. doi: 10.1093/bfgp/elv050. Epub 2015 Nov 20. Review.

9.

Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.

Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR.

Eur Urol. 2016 Apr;69(4):646-657. doi: 10.1016/j.eururo.2015.08.007. Epub 2015 Aug 19. Review.

10.

Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival.

Choudhry H, Albukhari A, Morotti M, Haider S, Moralli D, Smythies J, Schödel J, Green CM, Camps C, Buffa F, Ratcliffe P, Ragoussis J, Harris AL, Mole DR.

Oncogene. 2015 Aug 20;34(34):4546. doi: 10.1038/onc.2014.431.

PMID:
26289678
11.

Heterogeneous Effects of Direct Hypoxia Pathway Activation in Kidney Cancer.

Salama R, Masson N, Simpson P, Sciesielski LK, Sun M, Tian YM, Ratcliffe PJ, Mole DR.

PLoS One. 2015 Aug 11;10(8):e0134645. doi: 10.1371/journal.pone.0134645. eCollection 2015.

12.

Destruction of a distal hypoxia response element abolishes trans-activation of the PAG1 gene mediated by HIF-independent chromatin looping.

Schörg A, Santambrogio S, Platt JL, Schödel J, Lindenmeyer MT, Cohen CD, Schrödter K, Mole DR, Wenger RH, Hoogewijs D.

Nucleic Acids Res. 2015 Jul 13;43(12):5810-23. doi: 10.1093/nar/gkv506. Epub 2015 May 24.

13.

Tumor hypoxia induces nuclear paraspeckle formation through HIF-2α dependent transcriptional activation of NEAT1 leading to cancer cell survival.

Choudhry H, Albukhari A, Morotti M, Haider S, Moralli D, Smythies J, Schödel J, Green CM, Camps C, Buffa F, Ratcliffe P, Ragoussis J, Harris AL, Mole DR.

Oncogene. 2015 Aug 20;34(34):4482-90. doi: 10.1038/onc.2014.378. Epub 2014 Nov 24. Erratum in: Oncogene. 2015 Aug 20;34(34):4546.

14.

Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis.

Couvé S, Ladroue C, Laine E, Mahtouk K, Guégan J, Gad S, Le Jeune H, Le Gentil M, Nuel G, Kim WY, Lecomte B, Pagès JC, Collin C, Lasne F, Benusiglio PR, Bressac-de Paillerets B, Feunteun J, Lazar V, Gimenez-Roqueplo AP, Mazure NM, Dessen P, Tchertanov L, Mole DR, Kaelin W, Ratcliffe P, Richard S, Gardie B.

Cancer Res. 2014 Nov 15;74(22):6554-64. doi: 10.1158/0008-5472.CAN-14-1161. Epub 2014 Nov 4.

15.

Archean komatiite volcanism controlled by the evolution of early continents.

Mole DR, Fiorentini ML, Thebaud N, Cassidy KF, McCuaig TC, Kirkland CL, Romano SS, Doublier MP, Belousova EA, Barnes SJ, Miller J.

Proc Natl Acad Sci U S A. 2014 Jul 15;111(28):10083-8. doi: 10.1073/pnas.1400273111. Epub 2014 Jun 23.

16.

Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia.

Camps C, Saini HK, Mole DR, Choudhry H, Reczko M, Guerra-Assunção JA, Tian YM, Buffa FM, Harris AL, Hatzigeorgiou AG, Enright AJ, Ragoussis J.

Mol Cancer. 2014 Feb 11;13:28. doi: 10.1186/1476-4598-13-28.

17.

Extensive regulation of the non-coding transcriptome by hypoxia: role of HIF in releasing paused RNApol2.

Choudhry H, Schödel J, Oikonomopoulos S, Camps C, Grampp S, Harris AL, Ratcliffe PJ, Ragoussis J, Mole DR.

EMBO Rep. 2014 Jan;15(1):70-6. doi: 10.1002/embr.201337642. Epub 2013 Dec 21.

18.

miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis.

McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, Selby PJ, Banks RE, Harris AL.

Br J Cancer. 2013 Mar 19;108(5):1133-42. doi: 10.1038/bjc.2013.56. Epub 2013 Feb 28.

19.

Pan-genomic binding of hypoxia-inducible transcription factors.

Schödel J, Mole DR, Ratcliffe PJ.

Biol Chem. 2013 Apr;394(4):507-17. doi: 10.1515/hsz-2012-0351. Review.

PMID:
23324384
20.

Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression.

Schödel J, Bardella C, Sciesielski LK, Brown JM, Pugh CW, Buckle V, Tomlinson IP, Ratcliffe PJ, Mole DR.

Nat Genet. 2012 Mar 11;44(4):420-5, S1-2. doi: 10.1038/ng.2204.

21.

Regulation of hepcidin expression at high altitude.

Talbot NP, Lakhal S, Smith TG, Privat C, Nickol AH, Rivera-Ch M, León-Velarde F, Dorrington KL, Mole DR, Robbins PA.

Blood. 2012 Jan 19;119(3):857-60. doi: 10.1182/blood-2011-03-341776. Epub 2011 Nov 30.

22.

High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq.

Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR.

Blood. 2011 Jun 9;117(23):e207-17. doi: 10.1182/blood-2010-10-314427. Epub 2011 Mar 29.

23.

Regulation of type II transmembrane serine proteinase TMPRSS6 by hypoxia-inducible factors: new link between hypoxia signaling and iron homeostasis.

Lakhal S, Schödel J, Townsend AR, Pugh CW, Ratcliffe PJ, Mole DR.

J Biol Chem. 2011 Feb 11;286(6):4090-7. doi: 10.1074/jbc.M110.173096. Epub 2010 Oct 21.

24.

The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1.

Schietke R, Warnecke C, Wacker I, Schödel J, Mole DR, Campean V, Amann K, Goppelt-Struebe M, Behrens J, Eckardt KU, Wiesener MS.

J Biol Chem. 2010 Feb 26;285(9):6658-69. doi: 10.1074/jbc.M109.042424. Epub 2009 Dec 21.

25.

Iron homeostasis and its interaction with prolyl hydroxylases.

Mole DR.

Antioxid Redox Signal. 2010 Apr;12(4):445-58. doi: 10.1089/ars.2009.2790. Review.

PMID:
19650690
26.

Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts.

Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragoussis J, Ratcliffe PJ.

J Biol Chem. 2009 Jun 19;284(25):16767-75. doi: 10.1074/jbc.M901790200. Epub 2009 Apr 21.

27.

Regulation of growth differentiation factor 15 expression by intracellular iron.

Lakhal S, Talbot NP, Crosby A, Stoepker C, Townsend AR, Robbins PA, Pugh CW, Ratcliffe PJ, Mole DR.

Blood. 2009 Feb 12;113(7):1555-63. doi: 10.1182/blood-2008-07-170431. Epub 2008 Dec 1.

28.

Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha.

Pollard PJ, Loenarz C, Mole DR, McDonough MA, Gleadle JM, Schofield CJ, Ratcliffe PJ.

Biochem J. 2008 Dec 15;416(3):387-94. doi: 10.1042/BJ20081238.

PMID:
18713068
29.

Cellular oxygen sensing in health and disease.

Mole DR, Ratcliffe PJ.

Pediatr Nephrol. 2008 May;23(5):681-94. Epub 2007 Oct 23. Review.

PMID:
17955264
30.

Regulation of HIF: prolyl hydroxylases.

Stolze IP, Mole DR, Ratcliffe PJ.

Novartis Found Symp. 2006;272:15-25; discussion 25-36. Review.

PMID:
16686427
32.

Characterization of different isoforms of the HIF prolyl hydroxylase PHD1 generated by alternative initiation.

Tian YM, Mole DR, Ratcliffe PJ, Gleadle JM.

Biochem J. 2006 Jul 1;397(1):179-86.

33.

Hypoxia-inducible factors: where, when and why?

Gleadle JM, Mole DR, Pugh CW.

Kidney Int. 2006 Jan;69(1):15-7.

34.

HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability.

Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L.

Cancer Cell. 2005 Aug;8(2):143-53.

35.

Determination and comparison of specific activity of the HIF-prolyl hydroxylases.

Tuckerman JR, Zhao Y, Hewitson KS, Tian YM, Pugh CW, Ratcliffe PJ, Mole DR.

FEBS Lett. 2004 Oct 8;576(1-2):145-50.

37.

2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase.

Mole DR, Schlemminger I, McNeill LA, Hewitson KS, Pugh CW, Ratcliffe PJ, Schofield CJ.

Bioorg Med Chem Lett. 2003 Aug 18;13(16):2677-80.

PMID:
12873492
38.

Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases.

Schlemminger I, Mole DR, McNeill LA, Dhanda A, Hewitson KS, Tian YM, Ratcliffe PJ, Pugh CW, Schofield CJ.

Bioorg Med Chem Lett. 2003 Apr 17;13(8):1451-4.

PMID:
12668010
39.
40.

Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.

Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ.

IUBMB Life. 2001 Jul;52(1-2):43-7. Review.

41.

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, Ratcliffe PJ.

Cell. 2001 Oct 5;107(1):43-54.

42.

Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.

Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER.

Hum Mol Genet. 2001 May 1;10(10):1029-38.

PMID:
11331613
43.

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ.

Science. 2001 Apr 20;292(5516):468-72. Epub 2001 Apr 5.

44.

Renal complications of jejuno-ileal bypass for obesity.

Mole DR, Tomson CR, Mortensen N, Winearls CG.

QJM. 2001 Feb;94(2):69-77. Review.

PMID:
11181982
45.

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.

J Biol Chem. 2000 Aug 18;275(33):25733-41.

46.

An unusual complication of pregnancy.

Ong AC, Mole DR, Altmann P.

Nephrol Dial Transplant. 1999 May;14(5):1324-6. No abstract available.

PMID:
10344394
47.

Postprandial alkaline tide: does it exist?

Johnson CD, Mole DR, Pestridge A.

Digestion. 1995;56(2):100-6.

PMID:
7750662
48.

Sites of deposition of aqueous aerosols: a study of efficiency of delivery systems for lung ventilation imaging in man.

Woolman PS, Coutts CT, Mole DR, Dendy PP, Higenbottam TW.

Nucl Med Commun. 1989 Mar;10(3):171-80.

PMID:
2657514

Supplemental Content

Support Center